Undermeasurement of Nuchal Translucencies: Implications for Screening
暂无分享,去创建一个
[1] M. Evans,et al. Impact of Quality of Nuchal Translucency Measurements on Detection Rates of Trisomies 13 and 18 , 2010, Fetal Diagnosis and Therapy.
[2] J. Canick,et al. Technical standards and guidelines: Prenatal screening for Down syndrome that includes first-trimester biochemistry and/or ultrasound measurements , 2009, Genetics in Medicine.
[3] K. Kagan,et al. A mixture model of nuchal translucency thickness in screening for chromosomal defects , 2008, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[4] H. Cuckle,et al. Biochemical screening for aneuploidy , 2007 .
[5] R. Galen,et al. Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol. , 2007, American journal of obstetrics and gynecology.
[6] A. Rudnicka,et al. First-trimester or second-trimester screening, or both, for Down's syndrome. , 2005, The New England journal of medicine.
[7] W. Encinosa,et al. Technology in American Health Care: Policy Directions for Effective Evaluation and Management , 2004 .
[8] R. Snijders,et al. First-trimester screening for trisomies 21 and 18. , 2004, The New England journal of medicine.
[9] M. Evans,et al. The introduction of new technologies , 1997 .
[10] W. Edwards Deming,et al. Out of the Crisis , 1982 .
[11] K. Nicolaides,et al. Nuchal translucency measurements for first-trimester screening: the 'price' of inaccuracy. , 2007, Fetal diagnosis and therapy.
[12] R. Galen,et al. Beyond Normality: The Predictive Value and E ciency of Medical Diagnoses , 1975 .